130 related articles for article (PubMed ID: 1381438)
41. Comparison of selective polymerase chain reaction primers and differential probe hybridization of polymerase chain reaction products for determination of relative amounts of codon 215 mutant and wild-type HIV-1 populations.
Eastman PS; Urdea M; Besemer D; Stempien M; Kolberg J
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):264-73. PubMed ID: 7540490
[TBL] [Abstract][Full Text] [Related]
42. Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy.
Race E; Gilbert SM; Sheldon JG; Rose JS; Moffatt AR; Sitbon G; Dissanayeke SR; Cammack N; Duncan IB
AIDS; 1998 Aug; 12(12):1465-74. PubMed ID: 9727567
[TBL] [Abstract][Full Text] [Related]
43. Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.
Nielsen C; Bruun L; Mathiesen LR; Pedersen C; Gerstoft J
AIDS; 1996 Jun; 10(6):625-33. PubMed ID: 8780817
[TBL] [Abstract][Full Text] [Related]
44. Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates.
Lafeuillade A; Poggi C; Hittinger G; Chadapaud S
HIV Med; 2001 Oct; 2(4):231-5. PubMed ID: 11737402
[TBL] [Abstract][Full Text] [Related]
45. Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy.
Smith MS; Koerber KL; Pagano JS
J Infect Dis; 1994 Jan; 169(1):184-8. PubMed ID: 7506280
[TBL] [Abstract][Full Text] [Related]
46. Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing.
Reinis M; Vandasová J; Stanková M; Linka M; Brůcková M
Acta Virol; 2001; 45(5-6):279-86. PubMed ID: 12083326
[TBL] [Abstract][Full Text] [Related]
47. Correlation between antiretroviral resistance mutations, biological parameters, and clinical evolution in zidovudine-treated patients infected with human immunodeficiency virus type 1.
Leriche-Guérin K; Trabaud MA; Cotte L; Bissuel F; Deruelle E; Rougier P; Trépo C
Eur J Clin Microbiol Infect Dis; 1997 Sep; 16(9):660-8. PubMed ID: 9352259
[TBL] [Abstract][Full Text] [Related]
48. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance.
Conlon CP; Klenerman P; Edwards A; Larder BA; Phillips RE
J Infect Dis; 1994 Feb; 169(2):411-5. PubMed ID: 7508970
[TBL] [Abstract][Full Text] [Related]
49. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group.
Japour AJ; Mayers DL; Johnson VA; Kuritzkes DR; Beckett LA; Arduino JM; Lane J; Black RJ; Reichelderfer PS; D'Aquila RT
Antimicrob Agents Chemother; 1993 May; 37(5):1095-101. PubMed ID: 8517697
[TBL] [Abstract][Full Text] [Related]
50. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.
Kellam P; Boucher CA; Larder BA
Proc Natl Acad Sci U S A; 1992 Mar; 89(5):1934-8. PubMed ID: 1371886
[TBL] [Abstract][Full Text] [Related]
51. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.
Picard V; Angelini E; Maillard A; Race E; Clavel F; Chêne G; Ferchal F; Molina JM
J Infect Dis; 2001 Sep; 184(6):781-4. PubMed ID: 11517441
[TBL] [Abstract][Full Text] [Related]
52. Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients.
Paolucci S; Baldanti F; Campanini G; Zavattoni M; Cattaneo E; Dossena L; Gerna G
J Med Virol; 2001 Oct; 65(2):207-17. PubMed ID: 11536225
[TBL] [Abstract][Full Text] [Related]
53. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.
Japour AJ; Welles S; D'Aquila RT; Johnson VA; Richman DD; Coombs RW; Reichelderfer PS; Kahn JO; Crumpacker CS; Kuritzkes DR
J Infect Dis; 1995 May; 171(5):1172-9. PubMed ID: 7538548
[TBL] [Abstract][Full Text] [Related]
54. The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA.
Kaye S; Comber E; Tenant-Flowers M; Loveday C
AIDS Res Hum Retroviruses; 1995 Oct; 11(10):1221-5. PubMed ID: 8573378
[TBL] [Abstract][Full Text] [Related]
55. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients.
Mohri H; Singh MK; Ching WT; Ho DD
Proc Natl Acad Sci U S A; 1993 Jan; 90(1):25-9. PubMed ID: 7678340
[TBL] [Abstract][Full Text] [Related]
56. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors.
Sugiura W; Matsuda M; Matsuda Z; Abumi H; Okano A; Oishi T; Moriya K; Yamamoto Y; Fukutake K; Mimaya J; Ajisawa A; Taki M; Yamada K; Nagai Y
J Hum Virol; 1999; 2(3):146-53. PubMed ID: 10413366
[TBL] [Abstract][Full Text] [Related]
57. Clinical correlates of in vitro HIV-1 resistance ot zidovudine. Results of the Multicentre Canadian AZT Trial.
Montaner JS; Singer J; Schechter MT; Raboud JM; Tsoukas C; O'Shaughnessy M; Ruedy J; Nagai K; Salomon H; Spira B
AIDS; 1993 Feb; 7(2):189-96. PubMed ID: 8466681
[TBL] [Abstract][Full Text] [Related]
58. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine.
de Jong MD; Veenstra J; Stilianakis NI; Schuurman R; Lange JM; de Boer RJ; Boucher CA
Proc Natl Acad Sci U S A; 1996 May; 93(11):5501-6. PubMed ID: 8643604
[TBL] [Abstract][Full Text] [Related]
59. Development and significance of zidovudine resistance in children infected with human immunodeficiency virus.
Ogino MT; Dankner WM; Spector SA
J Pediatr; 1993 Jul; 123(1):1-8. PubMed ID: 8100579
[TBL] [Abstract][Full Text] [Related]
60. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
